News tagged ‘ChildhoodCancer’ clear
- Dana-Farber/Children's Hospital Cancer Center researchers have linked genetic mutations to each of the four recognized subtypes of medulloblastoma, the most common malignant brain tumor of children.
Tags: BasicResearch, ChildhoodCancer, Genomics, BrainTumors
- Dana-Farber/Boston Children's researchers reported promising outcomes data for the first group of boys with X-linked severe combined immunodeficiency syndrome (SCID-X1), a fatal genetic immunodeficiency also known as "bubble boy" disease, who were treated in an international clinical study of a new form of gene therapy.
Tags: ChildhoodCancer, ImmuneSystem, Genetics, Leukemia
- Pediatric patients with B-precursor acute lymphoblastic leukemia who are likely to relapse after chemotherapy treatment can reduce those odds by receiving additional courses of chemotherapy, according to research by Dana-Farber/Children's Hospital Cancer Center investigators.
Tags: chemotherapy, ChildhoodCancer, Leukemia
- An irregularity within many neuroblastoma cells may indicate whether the tumor is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors.
- Physicians who inform parents of children with cancer about the likely
course of the disease can provide hope, even when the child's prognosis
is poor, according to a Dana-Farber Cancer Institute study presented at a
press briefing at the American Society of Clinical Oncology annual
- Researchers at Dana-Farber and Children's Hospital Boston have shown that changes in the structure of DNA are responsible for hard-to-treat MLL leukemia – and that it's possible to reverse this process.
Tags: BasicResearch, ChildhoodCancer
- A national drug shortage has been linked to a higher rate of relapse among Hodgkin lymphoma patients enrolled in a national pediatric clinical trial, report researchers involved in the study.
Tags: chemotherapy, ChildhoodCancer, Lymphoma
- When the eye cancer retinoblastoma is diagnosed in racial and ethnic minority children whose families don't have private health insurance, it often takes a more invasive course than in other children, probably because of delays in diagnosis, according to researchers at Dana-Farber/Children's Hospital Cancer Center in Boston.
Tags: ChildhoodCancer, Disparities
- David G. Nathan, MD, president emeritus of Dana-Farber Cancer Institute and physician-in-chief emeritus of Boston Children's Hospital, was honored as the inaugural recipient of the Boston Children’s Hospital Lifetime Impact Award at the hospital’s second Annual Global Pediatric Innovation Summit, Taking on Tomorrow (#PedInno14).
Tags: ChildhoodCancer, Honors
Showing 21-30 of 40 items